生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | PIKfyve is the mammalian type III PtdInsP kinase that acts on PtdIns3P (phosphatidylinositol 3-phosphate) to generate PtdIns(3,5)P2. PtdIns(3,5)P2 has been shown to have a role in the retrieval of cargoes to the trans-Golgi network (TGN), and has been implicated in insulin-regulated IRAP/GLUT4 vesicle transport. YM201636 is a novel, potent and selective inhibitor of PIKfyve, with a half-maximal inhibitory concentration (IC50) of 33 nM. An IC50 for PtdIns3P p110α was determined to be 3 μM, almost 100-fold higher than for PIKfyve. In serum-starved NIH3T3 cells, YM201636 at 800 nM decreased PtdIns(3,5)P2 production by 80%. Acute treatment with YM201636 of various cell types, including mouse embryonic fibroblasts (MEFs), Madin–Darby canine kidney (MDCK), MCF10A, COS7 and NIH3T3 cells, caused the formation of large vesicular structures. The size and rate of formation are time- and concentration-dependent, with an A50 of around 400 nM. In NIH3T3 cells treated with 800 nM YM201636 for 2 h, YM201636 became concentrated on the surface of a subset of enlarged vesicular structures and on some lumenal vesicles. When NIH3T3 cells were treated with YM201636, it was apparent that most of LC3 (the GFP(green fluorescent protein)-tagged autophagosome marker) accumulated inside the enlarged vesicles[2]. YM201636 almost completely inhibited basal and insulin-activated 2-deoxyglucose uptake at doses as low as 160 nM, with an IC50 of 54 nM for the net insulin response. In addition to PIKfyve, YM201636 also completely inhibited insulin-dependent activation of class IA PI 3-kinase[3]. |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
2.14mL 0.43mL 0.21mL |
10.70mL 2.14mL 1.07mL |
21.39mL 4.28mL 2.14mL |
参考文献 |
---|